In 2024, Pfizer generated total revenues of some 63.6 billion U.S. dollars. For Q4, 2024, the company reported revenues of some 17.8 billion U.S. dollars. That was significantly higher than 14.6 billion dollars in Q4 2023. By failing to prepare, you are preparing to fail The majority of Pfizer’s revenue comes from the manufacture and sale of its products. Pharmaceutical companies are always planning for the future, looking for ways to offset the impact felt when those products start to lose market exclusivity. The development of products is essential for the continued growth of the company, and investing in research and development (R&D) is one way of identifying new, innovative medicines. Pfizer’s R&D expenditure stood at around 10.8 billion U.S. dollars in 2024. Why Pfizer’s revenues decreased until 2020? Pfizer averaged quarterly revenues of around 13.2 billion U.S. dollars in the four years from the start of 2016 to the end of 2019 – this is considerably lower than the 16.7 billion U.S. dollars the company averaged per quarter in 2010. One reason for the decline was competition from generic drugs that entered the market when key patents expired. Pfizer lost the market exclusivity for its Lipitor product at the end of 2011, and revenues were greatly affected as a consequence. Additionally, following a review of its product portfolio, Pfizer’s revenues were also impacted by the decision to spin off some of its business segments, such as its animal health division in 2013 and its Upjohn business in 2020.

Sales from the United States contributed more than 38 billion U.S. dollars towards Pfizer's total revenue of around 63.6 billion U.S. dollars in 2023. Pfizer sees strong growth in emerging markets Pfizer’s total revenue is divided into four geographic areas: the United States, Developed Markets, and Emerging Markets. China is one of the company’s largest single markets behind the United States, which contributed 60 percent of Pfizer’s total revenue. Pfizer continues to support investment in emerging markets, but the vulnerable nature of these countries means strategies come with an element of risk due to unforeseen financial or political events, for example. The power of product patents Managing the expiration of key patents is one of the greatest challenges facing Pfizer because competition from generic versions can make a big difference to company revenues. Many of Pfizer’s leading products enjoy the security of market exclusivity, but less expensive generic versions are free to enter the market when these property rights end. In 2019, Pfizer anticipated a fall in sales revenue from China due to significant competition from generic versions.

Pfizer is a global pharmaceutical company and among the top pharmaceutical companies in the world. Pfizer is headquartered in New York City. In 2024, the company's total revenue stood at 63.6 billion U.S. dollars. Pfizer’s global positioning Pfizer’s products are available in many countries worldwide and as of 2024, the company had more than 200 research and development projects in the pipeline. For several years, Pfizer was the top pharmaceutical company based on global prescription drug sales and is among the leading pharmaceutical companies based on research and development (R&D) spending. Pfizer’s largest segment is Innovative Health (IH). The Innovative Health business focuses on various rare diseases, vaccines, immunology and internal medicine to name a few. Pfizer’s top products In 2024, products from the Prevnar family were among Pfizer's top products based on revenue. However, Pfizer has several other drugs that are also well-known. For example, Lipitor (atorvastatin calcium) is used in the treatment of high cholesterol. Over the years, however, Lipitor revenues have been on the decline due to patent loss, yet it remains part of Pfizer’s top products. One of Pfizer’s most well-known products, Viagra (sildenafil citrate), used in the treatment of erectile disfunction, has also been on the decline with 2019 having the lowest revenues on record. The low revenues are mainly attributable to Viagra’s loss of patent exclusivity in the U.S. in December 2017.

Pfizer surpasses Q4 and FY 2024 earnings expectations, with a strategic focus on cost reductions and revenue growth, overcoming challenges such as patent expirations and Medicare negotiations.

Pfizer generated a net income of over eight billion U.S. dollars in 2024. The company reported basic net earnings per common share of 1.42 U.S. dollars. The impact of rising costs on earnings per share The net income of Pfizer dramatically increased around fourfold between 2023 and 2024, evident in the company’s net earnings per share, which increased by over one U.S. dollar. Rising research and development costs can be a contributing factor in the decrease in the net income. In relation to revenues, the pharmaceutical industry is one of the biggest investors in research and development. Revenues increased due to COVID-19 vaccine Thanks to record-breaking sales of COVID-19 vaccine Comirnaty, Pfizer generated its highest total revenues in the years 2021 and 2022. In general, the majority of Pfizer’s revenues comes from the manufacture and sale of its products, and revenues from the company’s domestic market of the United States accounts for a share of around 60 percent. Pfizer sells its pharmaceutical products in more than 125 countries worldwide, with the United States, China, and Japan being its three largest markets.

Pfizer's annual net income per employee was $99.15K in fiscal year 2024. The net income per employeeincreased$75.07Kfrom $24.08K(in 2023) to $99.15K (in 2024), representing a 311.75% year-over-year growth.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data was reported at 1,753,000.000 USD th in Jun 2018. This records an increase from the previous number of 812,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data is updated quarterly, averaging 1,980,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 3,433,000.000 USD th in Dec 2017 and a record low of 707,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed Rest of World data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data was reported at 2,835,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,314,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data is updated quarterly, averaging 3,304,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 5,806,000.000 USD th in Dec 2014 and a record low of 1,174,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data was reported at 2,340,000.000 USD th in Sep 2018. This records an increase from the previous number of 1,591,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data is updated quarterly, averaging 2,277,000.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 4,442,000.000 USD th in Dec 2015 and a record low of 778,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: International: Developed EU data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

The net income of Pfizer stood at some eight billion U.S. dollars in 2024. In the preceding year, the net income was at over 2.1 billion U.S. dollars. What factors affect net income? Companies discover how much they have earned or lost during an accounting period by analyzing their net income. For example, rising costs are among several reasons for the significant fall in Pfizer’s net income in 2020: the company increased its research and development expenditure, and suffered additional costs associated with the restructuring of the organization. It is worth adding that the high net income in 2017 was favorably impacted by a tax benefit of around nine billion U.S. dollars. The pros and cons of mergers and acquisitions Mergers and acquisitions are a common business strategy used by companies looking to grow. Three of the largest deals in pharmaceutical industry history involve Pfizer, including its acquisition of Warner-Lambert for a record fee of around 90 billion U.S. dollars in 2000. Advantages of the tactic include a larger workforce, increased spending budgets, and breaking into new markets. However, a failure to anticipate potential problems can be damaging to a company. For instance, the integration may disrupt current business operations, and inconsistencies may start to appear in standards and procedures.

United States US: PFE: Revenue (External): Innovative Health Product: US data was reported at 9,121,000.000 USD th in Jun 2018. This records an increase from the previous number of 4,544,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: US data is updated quarterly, averaging 9,025,500.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 18,460,000.000 USD th in Dec 2017 and a record low of 2,972,000.000 USD th in Mar 2015. United States US: PFE: Revenue (External): Innovative Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Essential Health Product: International data was reported at 10,238,000.000 USD th in Sep 2018. This records an increase from the previous number of 6,891,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: International data is updated quarterly, averaging 8,591,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 14,836,000.000 USD th in Dec 2015 and a record low of 3,220,000.000 USD th in Mar 2017. United States US: PFE: Revenue (External): Essential Health Product: International data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

U.S. experts predict a smaller winter COVID wave, posing challenges for Pfizer amid declining revenues, emphasizing the need to diversify non-COVID products.

United States US: PFE: Revenue (External): Essential Health Product: US data was reported at 4,859,000.000 USD th in Sep 2018. This records an increase from the previous number of 3,379,000.000 USD th for Jun 2018. United States US: PFE: Revenue (External): Essential Health Product: US data is updated quarterly, averaging 4,849,500.000 USD th from Jun 2015 (Median) to Sep 2018, with 14 observations. The data reached an all-time high of 9,596,000.000 USD th in Dec 2016 and a record low of 1,731,000.000 USD th in Mar 2018. United States US: PFE: Revenue (External): Essential Health Product: US data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data was reported at 2,394,000.000 USD th in Jun 2018. This records an increase from the previous number of 1,158,000.000 USD th for Mar 2018. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data is updated quarterly, averaging 2,571,000.000 USD th from Sep 2014 (Median) to Jun 2018, with 16 observations. The data reached an all-time high of 4,381,000.000 USD th in Dec 2017 and a record low of 872,000.000 USD th in Mar 2016. United States US: PFE: Revenue (External): Innovative Health Product: International: Emerging markets data remains active status in CEIC and is reported by Pfizer Incorporation. The data is categorized under World Trend Plus’s Top Company: Pharmaceutical and Biotechnology: Non-Asia – Table RT.NA002: Pfizer Incorporation (PFE): Financial Data Breakdowns & Operational Data.

Pfizer reported $739M in Interest Expense on Debt for its fiscal quarter ending in December of 2024. Data for Pfizer | PFE - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last March in 2025.

Discover Novavax's strategic efforts as it reports reduced Q4 losses amid declining COVID-19 vaccine sales, focusing on future growth through new product development and a key deal with Sanofi.

Pfizer’s worldwide known erectile dysfunction product Viagra generated around 500 million U.S. dollars in revenue in 2019. Sales of this drug have decreased steadily over the past seven years, especially because patent protection expired outside the U.S. in 2012. In the United States, several drug manufacturers are currently allowed to market generic versions of Viagra (sildenafil), even if the patent is set to expire in 2020. This was the reason behind a further significant decline in sales in 2017-2018.

Drug manufacturer Pfizer
Drug manufacturer Pfizer is currently the world’s leading pharmaceutical company based on pure pharmaceutical sales of prescribed and over-the-counter drugs. The company is headquartered in Midtown Manhattan, New York City. Until 2013, the company also had a notable animal health product line. Today, the company is totally focused on human medicine, divided into two major segments - Innovative Health and Essential Health. Pfizer generates nearly half of its revenues inside the United States.

The rise of Viagra
Viagra was developed by scientists that were originally working on a drug for the treatment of hypertension and angina pectoris. During one of the trial phases the ‘adverse effect’ became obvious – while the targeted angina pectoris showed no improvement. Thus, it was approved for the market as an orally administered drug for erectile dysfunction in 1998. Pfizer’s Viagra has surely been one of the best-known and most discussed pharmaceutical products over the last few decades, entering even popular culture and becoming a synonym for potency. The drug, however, is also approved for treating pulmonary arterial hypertension.

Get the sample copy of Respiratory Diseases Drugs Market Report 2025 (Global Edition) which includes data such as Market Size, Share, Growth, CAGR, Forecast, Revenue, list of Respiratory Diseases Drugs Companies (Biogen, Pfizer, Teva, Novartis, Johnson & Johnson, EliLilly, Otsuka, Merck, AstraZeneca, Novartis, Takeda), Market Segmented by Type (OTC, Rx Drugs), by Application (Hospital, Retail Pharmacy)

Moderna generated total revenues of some 3.2 billion U.S. dollars in 2024, a massive decrease compared to the years before. The drop was mainly due to the decreasing demand for its COVID-19 vaccine Spikevax. Working hard to produce the first 'blockbuster' Moderna is a clinical stage biotech company that is pioneering messenger RNA (mRNA) therapeutics and vaccines. Beside its COVID-19 vaccine, the company is yet to generate revenues from the sale of potential drugs, and this will remain the same until it successfully completes clinical development and obtains regulatory approval for one of its medicines. Like many other biotech companies, Moderna invests significant amounts of money into research and development projects, and annual costs continue to grow. One of the very first COVID-19 vaccines approved Moderna, in partnership with the National Institutes of Health (NIH) and the Coalition for Epidemic Preparedness Innovations (CEPI), was one of the very first to develop a vaccine to fight COVID-19. The vaccine codenamed mRNA-1273 – designed and manufactured in only 25 days – prevents future infections of the novel coronavirus that has caused the pandemic. The Moderna vaccine successfully went through all necessaryclinical phases, and was the second vaccine - after the Biontech/Pfizer vaccine - to be approved for widely usage already in late 2020.